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Executive Summary 
 Obstructive sleep apnea (OSA) includes symptoms of excessive daytime 
somnolence, snoring, and witnessed apneic events. 
 The average number of hypopneic and apneic events per hour of sleep are used 
to grade the severity of OSA using the apnea-hypopnea index. 
 The gold standard for diagnosing OSA is through full-night polysomnography in a 
laboratory with a titration to determine the optimal pressure setting. 
 Split-night diagnostic titration studies using auto-titration devices are not the 
diagnostic study of choice. 
 Continuous positive airway pressure (CPAP) devices remain the mainstay of 
treatment. If CPAP is poorly tolerated, alternatives include Bi-level PAP, oral 
devices, and surgical options. 
 Emerging therapies, such as hypoglossal nerve stimulation, are being developed. 
These alternatives to CPAP are being studied in efforts to improve patient 
adherence and outcomes associated with OSA. 
Definition 
In 2009, the Adult Obstructive Sleep Apnea Task Force of the American Academy of 
Sleep Medicine (AASM) defined obstructive sleep apnea (OSA) as “the occurrence of 
daytime sleepiness, loud snoring, witnessed breathing interruptions, or awakening due 
to gasping or choking in the presence of at least six obstructive respiratory events 
(apneas, hypopneas, or respiratory effort related arousals per hour of sleep). The 
presence of 15 or more obstructive respiratory events per hour of sleep in the absence 
of sleep-related symptoms is also sufficient for the diagnosis of OSA”.1 The symptoms 
of OSA are summarized in Table 1. 
AASM defines hypopneas as a “reduction in airflow,” while an obstructive apnea is a 
“complete cessation of airflow despite ongoing inspiratory efforts.”2 This can lead to a 
reduction in oxyhemoglobin saturation and arousal from sleep. The apnea-hypopnea 
index (AHI) is used to assess the severity of sleep apnea. 
Epidemiology 
OSA is the most common sleep-related disorder.3 Although the exact prevalence is 
unknown, estimates range from 10-17% in the United States.4 Improvements in 
diagnostic technology and more clearly defined diagnostic criteria appear to point to 
higher prevalence of OSA than previously believed, as high 23.4% in women and 49.7% 
in men.5 Diseases that increase risk for OSA include: obesity, atrial fibrillation, 
cardiovascular disease, cerebrovascular disease, congestive heart failure, Type 2 
diabetes mellitus (T2DM), pulmonary hypertension, and resistant hypertension.1,6Severe 
untreated OSA has been associated with increased all-cause mortality.3,4 
 
Race 
A racial disparity exists in OSA. African Americans appear to develop sleep-disordered 
breathing approximately 8 years earlier than Caucasians, and patients younger than 25 
years of age had higher numbers of apneic events.7 OSA rates in Asia appear to be 
similar to that of the United States, despite lower body mass index (BMI). Craniofacial 
and soft tissue differences in the upper airway increase the chance of OSA and are 
thought to explain why Asians have similar rates of OSA.1,8 
Obesity 
Obstructive sleep apnea is twice as prevalent in obese compared to normal weight 
individuals.9 According to the United States National Health and Nutrition Examination 
Survey database, estimated prevalence of OSA increased by as much as 50% between 
1990 and 2010 in every age and BMI category studied.10 Growing rates of obesity will 
continue to contribute to an increasing OSA prevalence.11 Over a 4-year period, the 
Wisconsin Sleep Cohort Study demonstrated worsening AHI with higher levels of 
obesity.3 
Gender 
Men are two to three times more likely to have OSA.12 The mechanism for why this 
disparity exists is poorly understood. This difference in risk is independent of age and 
BMI.8 However, during menopause, the prevalence of OSA in women is closer to that of 
men.12 
Age 
Young adulthood through the seventh decade is most affected by OSA.3,13 Rates 
increase with age, particularly in adults older than 60 years.4 Age-related reasons for 
increased OSA rates include changes in the pharyngeal bony and soft-palate structures 
and increased adiposity.6 In pediatric patients, high-risk groups for sleep apnea include 
the obese, those with adenoid and tonsillar hypertrophy, craniofacial abnormalities, 
Down syndrome, and neuromuscular disorders.16,17 The overall prevalence in children is 
1-5%.18 
Other Risk Factors 
Although less evidence exists, some observational studies report higher levels of OSA 
in smokers and those with chronic rhinitis, congestive heart failure, chronic obstructive 
pulmonary disease, cerebrovascular accidents, end-stage renal disease, and 
hypothyroidism.6 
Public Health Impact 
The exact cost of OSA is unknown. In 2002, estimates of $132 billion were spent on 
OSA.20 Of the $132 billion, an estimated $15.9 billion was spent on the 800,000 crashes 
attributed to OSA.20 Noncommercial drivers having motor vehicle crashes are more 
likely to have OSA.13 A recent study of 1478 patients with OSA estimated an increased 
motor vehicle risk ratio of 2.45 among patients compared with control (P < 
0.001).21Treatment of OSA with CPAP does improve the driver’s performance and 
reduce the incidence of motor vehicle crashes.21,22 
Pathophysiology 
The pathophysiology of OSA, once thought to simply be due to recurrent obstruction in 
the upper airway resulting in apnea or hypopnea, is now thought to be more complex 
and variable than this original theory.1 In most patients, multiple underlying factors lead 
to development of OSA. Some common examples include anatomical compromise in 
the pharyngeal airway, craniofacial anatomical features, dilator muscle weakness and/or 
dysfunction, supine/positional sleep apnea, unstable ventilatory control leading to 
imbalances in carbon dioxide and oxygen pressure levels, and lower thresholds for 
arousal from sleep.4,23 This cascade of events, alone or in combination, leads to 
physiologic changes in the body that result in the late cardiovascular, cerebrovascular, 
and psychological changes associated with untreated apnea.24 Figure 1 demonstrates 
the pathophysiology consequences of OSA. 
Figure 1. Physiologic Factors, Risk Factors, Treatment, and Comorbidities of OSA 
PNA = parasympathetic nervous system, SNA = sympathetic nervous system 
 
  
Screening for Obstructive Sleep Apnea 
The United States Preventive Services Task Force (USPSTF) is expected to make a 
recommendation for routine screening of OSA by 2016.25 Currently, the USPSTF does 
not have a recommendation for routine OSA screening.25 Concordantly, the AASM does 
not recommend universal screening for sleep apnea.1 Targeted diagnostic 
polysomnography (PSG) should occur if symptoms exist (see Table 1) or if risk factors, 
including obesity, craniofacial, or upper airway abnormalities, are present.1,11 
Table 1. Symptoms of Obstructive Sleep Apnea 
Daytime somnolence 
Difficulty concentrating or memory loss 
Fatigue 
Insomnia 
Mood changes 
Morning headaches 
Non-restorative sleep 
Table 1. Symptoms of Obstructive Sleep Apnea 
Snoring 
Vivid dreams 
Witnessed apnea 
Awakening due to gasping or choking 
  
There are multiple screening tools available. These scales are often utilized as a 
prescreen to help determine if a patient should undergo further testing. The Epworth 
Sleepiness Scale (ESS) is the most commonly used questionnaire to prescreen patients 
for OSA.4 As depicted in Table 2, ESS is self-administered and allows patients to rate 
their likelihood of falling asleep in eight daily activities.26,27 All questions must be 
answered for ESS to be a validated prescreen. A meta-analysis by the American 
College of Physicians determined this questionnaire had a low accuracy for diagnosis of 
OSA but that it does correlate with severity of OSA.4 A follow-up study by the ESS 
author determined a cutoff of > 10 is considered excessively sleepy.28 
Table 2. Epworth Sleepiness Scale (ESS) 
Use the following scale to choose the most appropriate number for each situation: 
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
It is important that you answer each question as best you can: 
Situation Chance of Dozing 
Watching TV 0 1 2 3 
Sitting, inactive in a public place (e.g., a theater or meeting) 0 1 2 3 
Sitting as a passenger in a car for an hour without a break 0 1 2 3 
Lying down to rest in the afternoon when circumstances permit 0 1 2 3 
Sitting and talking to someone 0 1 2 3 
Sitting quietly after a lunch without alcohol 0 1 2 3 
Sitting in a car, while stopped for a few minutes in the traffic 0 1 2 3 
Table 2. Epworth Sleepiness Scale (ESS) 
Use the following scale to choose the most appropriate number for each situation: 
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
It is important that you answer each question as best you can: 
Situation Chance of Dozing 
Scores of 0-9 indicate low possibility of OSA. 
Scores of 10-24 should seek expert care. 
Scores of 16 and greater indicate possibility of severe OSA or narcolepsy 
Adapted from: Johns MW. A new method for measuring daytime sleepiness: The Epworth 
sleepiness scale. Sleep 1991;14:540-545. 
Sitting and reading 0 1 2 3 
  
The same meta-analysis by the American College of Physicians demonstrated the 
Berlin Questionnaire, as depicted in Table 3, may be helpful in predicting risk for 
OSA.4The questionnaire had a wide range in sensitivity and specificity depending on the 
AHI cutoff level. Since no clinical model can predict severity of OSA,1,19 PSG remains the 
gold-standard for diagnosis of OSA.1 The Berlin Questionnaire and ESS have been 
used in multiple randomized, controlled studies, despite the lack of evidence.4 These 
questionnaires also have been used to monitor symptoms after initiating therapies for 
those diagnosed with OSA. These questionnaires are helpful to initiate discussions with 
at-risk patients. 
Table 3. Berlin Questionnaire 
Category 2 
6. How often do you feel tired or fatigued after your sleep? 
a. Nearly every day 
b. 3-4 times a week 
Table 3. Berlin Questionnaire 
c. 1-2 times a week 
d. 1-2 times a month 
e. never or nearly never 
7. During your wake time, do you feel tired, fatigued, or not up to par? 
a. Nearly every day 
b. 3-4 times a week 
c. 1-2 times a week 
d. 1-2 times a month 
e. never or nearly never 
8. Have you ever nodded off or fallen asleep while driving a vehicle? 
a. Yes b. No 
Category 3 
9. Do you have high blood pressure? 
a. Yes b. No c. Don’t know 
10. BMI > 30 kg/m2? 
a. Yes b. no 
To score, add points from each category. 
• Category 2 is positive if the total score is 2 or more points. 
• Category 3 is positive if the answer to item 9 is Yes OR if the BMI is > 30 kg/m2. 
High Risk for OSA: if there are 2 or more categories where the score is positive 
Low Risk for OSA : if there is 1 or no categories where the score is positive 
Category 1 
1. Do you snore? 
a. Yes b. No c. Don’t Know 
Table 3. Berlin Questionnaire 
If you snore 
2. Your snoring is? 
a. Slightly louder than breathing 
b. As loud as talking 
c. Louder than talking. 
d. Very loud. Can be heard in adjacent rooms. 
3. How often do you snore? 
a. Nearly every day 
b. 3-4 times per week 
c. 1-2 times per week 
d. 1-2 times a month 
e. never or nearly never 
4. Has your snoring ever bothered other people? 
a. Yes b. No 
5. Has anyone noticed that you quit breathing during your sleep? 
a. Nearly every day 
b. 3-4 times a week 
c. 1-2 times a week 
d. 1-2 times a month 
e. never or nearly never 
  
Diagnosis of OSA 
A thorough history and physical exam to evaluate for OSA should occur if a patient 
exhibits risk factors or symptomatology suggestive of sleep apnea. Common presenting 
complaints of OSA include snoring and daytime somnolence. In a systematic review of 
the accuracy of clinical examination in the diagnosis of OSA, the most useful individual 
findings for identifying patients with OSA was nocturnal choking or gasping. 
Snoring was less specific for identifying patients with OSA.29 Physical exam should 
include anthropometrics, such as neck circumference and BMI. A neck circumference > 
17 inches in men and > 16 inches in women warrants further investigation for OSA.1 A 
BMI > 30 kg/m2, which is diagnostic for obesity, is also an independent risk factor for 
OSA.1 The physical exam should include an evaluation of the mouth for uvula 
enlargement, tonsillar hypertrophy, and high arched/narrow hard palate, and the nose 
for polyps, septal deviation, and turbinate hypertrophy.   
The Mallampati score, a grading system of crowding in the oropharynx used by 
anesthesiologists to identify patients at risk for difficult intubation, was shown to be 
useful in evaluating patients at risk for OSA independent of other physical risk 
factors.30 Patients are graded on a scale of I-IV based on visualization of the uvula and 
soft palate with the mouth open and tongue protruded (see Figure 2). Patients are told 
to open their mouth and stick out their tongue as far as possible without emitting a 
sound. For every 1 point increase in the Mallampati score, the odds of having OSA 
increased by more than two-fold and the AHI increased by more than nine times. 
Figure 2. Mallampati Airway Classification (I-IV Scale) 
Class I: soft palate and entire uvula visible 
Class II: soft palate and portion of uvula visible 
Class III: soft palate visible (may include base of uvula) 
Class IV: soft palate not visible 
Figure 2. Mallampati Airway Classification (I-IV Scale) 
 
  
PSG at a sleep laboratory and home testing with portable monitors are two options for 
diagnosing OSA.1 Each testing has its limitations that will be further discussed. 
Polysomnography 
The AASM and the American College of Physicians recommend that PSG evaluation 
include “electroencephalogram, electrooculogram, chin electromyogram, airflow, oxygen 
saturation, respiratory effort, and electrocardiogram.”1,4 Furthermore, the AASM 
recommends testing for OSA only at an accredited sleep laboratory.1 PSG technicians 
should have training through an accredited sleep technologist education program or 
allied health education program.1 All PSGs should be evaluated by a board-certified 
sleep medicine physician. Full-night PSG should be used for diagnosis of OSA.1 The 
diagnosis of OSA is confirmed and graded using the AHI.1,15 The AHI is defined by the 
“number of obstructive events (apneas, hypopneas + respiratory event-related arousals) 
on PSG” per hour of sleep.1 The AASM threshold for diagnosing OSA is asymptomatic 
with AHI more than 15 events per hour or symptomatic (e.g., unintentional sleep 
episodes during daytime, daytime somnolence, fatigue, insomnia, waking up gasping or 
choking, confirmed snoring, breathing interruptions during sleep) with more than five 
events per hour. Table 4 demonstrates the AHI index with diagnosis and severity of 
OSA. High-quality evidence showed an association between AHI > 30 and greater with 
all-cause mortality.11 
Table 4. AHI Index, Diagnosis, and Severity of OSA 
AHI index = 15 without symptoms = OSA 
AHI index > 30 = severe OSA 
AHI index = 5 with symptoms = OSA 
  
Major limitations to PSG include high cost (ranging from hundreds to thousands of 
dollars depending on geographic location and facility fees), specialized resources, and 
time to complete study.11 This can be difficult for patients living in geographically rural 
areas. Underserved patients and those with transportation difficulties may also have 
difficulty completing PSG. 
Split-night Study 
A split-night study — an initial diagnostic PSG is followed by a CPAP titration on the 
same night — is an alternative to PSG testing.1 Split-night studies potentially require the 
patient to come to the sleep lab only once, cutting the cost of testing in half and 
decreasing the time burden required to diagnose and initiate treatment. However, this is 
not the recommended diagnostic technique because split-night studies have less time to 
diagnose hypopneic and apneic events and less time to perform a CPAP titration.19This 
may require the patient to return to the sleep lab an additional time to perform the CPAP 
titration.19 
Testing with Portable Monitors 
The AASM recommends portable monitors (PMs) should only be used in conjunction 
with a comprehensive sleep evaluation.1 The AASM recommends PMs should “record 
airflow, respiratory effort, and blood oxygenation.” Portable monitors are at-home testing 
devices and best for diagnosing OSA in patients with no comorbid sleep disorders or 
major medical problems.1,4,14 The American College of Physicians recommends PMs 
only for patients without serious comorbidities as an alternative to PSG when PSG is 
not available for diagnostic testing.4 Patients with a high likelihood of OSA and poor 
sleep quality and insomnia should undergo PSG.14 
When analyzing a PM test, the AHI for PMs is different than PSG. AHI for PMs is 
defined by AASM as “the number of apnea + hypopneas total recording time.”1 Since 
sleep duration is not recorded during home sleep testing, the total test time is used to 
calculate AHI and may underestimate events since the patient is likely to not have them 
when awake. PMs do not record body position, making a diagnosis of supine dominant 
OSA more difficult.15 
Overnight Pulse Oximetry 
During overnight pulse oximetry, the saturation of peripheral oxygen is estimated and 
recorded. Currently, overnight pulse oximetry is not recommended for diagnosis of 
OSA.25 However, emerging research demonstrates in a study of 619 patients that 
overnight pulse oximetry may be useful in the diagnosis of severe OSA with AHI ≥ 30. 
The overnight pulse oximetry provided an accuracy of 90.42-90.55% with sensitivity of 
89.36-89.87% and specificity of 91.08-93.05%. The sensitivity and specificity for 
diagnosis were lower for moderate OSA (AHI = 15).31 Larger studies are needed to 
evaluate the effectiveness of using this alternative method in OSA diagnosis. 
Treatment Options 
Weight loss, CPAP, and mandibular devices remain the cornerstone of therapy.1 There 
are different types of positive airway pressure (PAP) devices including bi-level 
(commonly known by the brand name BiPAP), continuous (CPAP), and autotitrating 
(APAP) modes. Patient preference should be considered when determining the delivery 
route for PAP, including nasal, oral, or oronasal. Patients who fail to utilize one type of 
mask should be offered an alternative prior to discontinuing PAP. Oral appliances, 
surgical options, and novel therapies to treat OSA are considered second-line therapies. 
Any severe disability or disorder causing decreased cognitive ability (i.e., Down 
syndrome, psychiatric diseases, and dementia) can make treating OSA difficult and may 
merit utilizing second-line therapies as initial treatment. 
Continuous Positive Airways Pressure 
CPAP is considered the gold standard treatment for patients with moderate and severe 
OSA.15,32 CPAP treatment using a facial mask was invented in 1981.3 Prior to this 
treatment, options were limited to dental devices, and for the most severe cases 
tracheotomy.3 
CPAP works by applying pressure to the pharyngeal lumen greater than the pharyngeal 
critical pressure. By maintaining pharyngeal patency, a decrease in hypopnea and 
apnea events occurs.32 
In a review article by the American College of Physicians, 22 studies compared CPAP 
to control, finding a reduction in AHI, improved ESS scores, and higher oxygen 
saturation levels.11 Additionally, 24 studies compared CPAP to sham CPAP treatments, 
finding moderate-quality evidence supporting CPAP as a superior treatment vs sham for 
AHI scores and ESS scores.11 
Benefits of CPAP include reduction of excessive daytime sleepiness, improved 
cognitive function, improved quality of life, reduced blood pressure in hypertensive 
patients, and overall reduction of cardiovascular mortality.32 Adherence to CPAP therapy 
is extremely variable (46-80%).32 Many reasons cause patients to be noncompliant with 
their therapy, including claustrophobia, discomfort, noise irritation, and skin irritation.11 
Predictors of adherence include more severe OSA, higher degree of daytime 
sleepiness, higher socioeconomic status, higher level of patient understanding of the 
therapy, and the type of mask used.32,33 Eight studies evaluated different types of masks, 
with adherence showing patients were much less adherent with oronasal masks 
compared to nasal masks.32 Nasal masks and nasal pillows had similar adherence but 
patients experienced more adverse symptoms (e.g., nasal congestion, nasal dryness, 
nosebleeds, headaches) with nasal pillows. From an efficacy standpoint, three small 
trials comparing oral CPAP vs nasal CPAP found insufficient evidence that one was 
superior to the other.11 
Auto-PAP   
An APAP is a PAP device that detects changes in a user’s respirations and can change 
the amount of pressure to maintain patency of airway. APAP and BiPAP are best suited 
for patients intolerant to CPAP.1 Moderate-quality evidence from 21 randomized trials 
demonstrated that APAP and fixed CPAP have similar adherence and treatment effects 
for patients with OSA.11 However, APAP is more expensive and can lead to more sleep 
fragmentation and hemodynamic effects compared to CPAP.15 
Bi-level PAP 
BiPAP devices are an alternative to CPAP for patients who have discomfort related to 
the fixed pressure of CPAP. BiPAP offers lower pressure during exhalation compared to 
inhalation. Insufficient evidence exists comparing BiPAP to CPAP.11 However, it is a 
beneficial alternative for those that cannot tolerate CPAP. 
Oral Appliances 
Oral appliances (OAs) can improve OSA symptoms by preventing collapsibility and 
maintaining the upper airway passage.34 Oral appliances are a good option for patients 
with mild-to-moderate OSA who are resistant to using CPAP.1,34,35 The AASM 
recommends all patients undergo a dental exam prior to use of OAs.1 This should occur 
6 months after fitting and then annually.1 
For all OAs, oropharyngeal crowding and obesity were predictive factors for response to 
oral appliance therapy.20 Multiple OAs currently available include mandibular advance 
devices (MAD), which cover the teeth and hold the mandible in place, and tongue 
stabilizing devices (TSD), which hold the tongue in a forward position. 
A Cochrane review in 2008 on OAs evaluated 17 studies with 831 participants. Two 
studies showed OAs reduced daytime sleepiness on ESS compared to controls with an 
improved AHI (AHI = -10.78 events/hr; 95% confidence interval [CI] = -15.53 to -
6.03).36Oral appliances were significantly less effective than CPAP at reducing AHI. In 
another study, OAs were compared to corrective upper airway surgery. OAs lowered 
symptoms and improved AHI for 12 months, while this did not remain after surgery.37 
Mandibular advancement devices are associated with successful treatment of OSA in 
small sample sizes. MAD efficacy is strongest in less obese, younger, female, mild 
OSA, and supine OSA patients.3,38 In a prospective, randomized, crossover study 
comparing MAD to CPAP, CPAP had better resolution of symptoms, patients preferred 
the MAD over CPAP, and patients reported higher levels of compliance.39 
Several novel OAs recently have been developed in an attempt to approve both the 
efficacy and adherence of treatment. A multicenter, prospective, randomized crossover 
trial on patients with mild to severe OSA was performed using an oral pressure therapy 
vacuum that works by pulling the soft palate forward and stabilizing the tongue when 
applied to the oropharynx. This device allows patients to breathe normally through their 
nose as continuous pressure is applied to the oral cavity. The study revealed that the 
appliance was well-tolerated and patients used it an average of 6 hours a night. 
Clinically significant improvements were seen in reduction of AHI, sleep quality and 
continuity, and daytime sleepiness symptoms.40 
TSDs help maintain the tongue in a more forward position to allow enhanced airway 
opening.41 A new TSD was studied in a randomized, crossover study on a small sample 
of patients in a tertiary sleep clinic. Patients were treated with both a TSD and MAD, 
and AHI, compliance, and device preference were monitored. Despite significant 
improvement in AHI with both devices, there was poor compliance with the TSD and 
patients preferred the MAD.41 
A limitation of OAs up to this point has been their inability to record objective data. 
Subjective data from patient reporting has been the only available data used in previous 
studies on OAs. A novel OA sensor device has recently been created that can be used 
to measure compliance. Initial research shows a high correlation between patient 
reporting and monitor data in regards to compliance with the OA.42 This new technology 
may prove invaluable for future studies of OAs. 
Surgical Options 
Prior to PAP methods, surgical interventions were commonly utilized as the only option 
to treat OSA.3 Table 5 delineates a list of common surgical procedures for OSA. With 
any surgical option, the patient should be informed of the risks, benefits, and 
alternatives. Possible side effects and complications should be explained. Surgical 
procedures should be considered when patients have obstructing anatomic structures 
that could be surgically corrected or when PAP therapy alone is insufficient.1 
Evidence supporting surgical intervention is lacking; surgical interventions compared to 
control, CPAP, and OAs were insufficient.11 There is consensus among experts that the 
best candidates for surgery are patients with known craniofacial structural 
abnormalities, and surgery should be performed in conjunction with CPAP treatment.1 
Bariatric surgery is recommended for any patients with BMI ≥ 40 kg/m2 or BMI ≥ 30 
kg/m2 with significant comorbidities (e.g., T2DM, hypertension), according to the Joint 
Statement of American Association of Clinical Endocrinologists, the Obesity Society, 
and the American Society for Metabolic and Bariatric Surgery.43 The AASM 
recommends bariatric surgery to be an adjunct to CPAP.1 Prior to bariatric surgery, 
CPAP should be initiated and re-evaluated after 10% weight loss. In a study of 767 
patients with untreated severe OSA with a BMI of 35-45 kg/m2, 35.5% were interested in 
bariatric surgery.44 Female gender and diagnosis of T2DM were most predictive of 
bariatric surgery interest.   
Table 5. Common Surgical Procedures for OSA by Site 
Nasal Procedures 
Oral, Oropharyngeal, and Nasopharyngeal Procedures 
 Uvulopalatopharyngoplasty & variations 
 Palatal advancement phargynoplasty 
 Tonsillectomy and/or adenoidectomy 
 Excision of tori mandibularis 
 Palatal implants 
Hypopharyngeal Procedures 
 Tongue reduction 
- Partial glossectomy 
- Tongue ablation 
- Lingual tonsillectomy 
 Tongue advancement/stabilization 
- Genioglossus advancement 
- Hyoid suspension 
- Mandibular advancement 
- Tongue suspension 
Laryngeal Procedures 
 Epiglottoplasty 
 Hyoid suspension 
Global Airway Procedures 
 Maxillomandibular advancement 
 Bariatric surgery 
Table 5. Common Surgical Procedures for OSA by Site 
Nasal Procedures 
Adapted from: Epstein LJ, Kristo D, Stollo PJ, et al. Clinical guideline for the evaluation, 
management and long-term care of obstructive sleep apnea in adults. J Clin Sleep 
Med 2009;5:263-276. 
 Septoplasty 
 Functional rhinoplasty 
 Nasal valve surgery 
 Turbinate reduction 
 Nasal polypectomy 
 Endoscopic procedure 
  
Nocturnal Supplemental Oxygen 
Studies have shown that supplemental oxygen can decrease nocturnal 
hypoxemia.45Supplemental oxygen does not reduce AHI when hypopnea is the reason 
for reduction in airflow. Although supplemental oxygen was more effective than control, 
it was less effective than CPAP for reducing AHI. Nocturnal supplemental oxygen does 
not lower 24-hour mean arterial pressure at 12 weeks when compared to 
CPAP.46 Interestingly, adherence to supplemental oxygen was higher than CPAP in a 
study group of 318 participants.46 
Novel Treatments 
Hypoglossal nerve stimulation therapy (HNS) has promising clinical therapeutic 
applications for OSA for patients who cannot tolerate or refuse to adhere to CPAP. In 
1978, Remmers et al first suggested that pharyngeal obstruction was related to loss of 
genioglossus muscle activity in OSA patients during sleep.20 A silicone cuff with 
electrodes is unilaterally surgically implanted around the hypoglossal nerve. The 
hypoglossal nerve innervates the protrusor and retractor muscles of the tongue, which 
are activated through continuous or synchronous stimulation from the electrodes.20Five 
recent trials on patients with OSA and BMI ≤ 40 kg/m2 showed > 50% reduction in AHI 
and the oxygen desaturation. Results were persistent at 12-month follow-up. A negative 
of the treatment was that the electrical stimulation induced arousal in patients and 
resulted in fragmented sleep.20 More research needs to be done on the possibility of 
alternate night therapy. When patients were discontinued from the therapy, the 
reductions in AHI and oxygen desaturation were present the following night and did not 
return to baseline for 5 nights.20 Furthermore, questions also exist about the proportion 
and type of patients that might best respond to HNS and whether this is cost effective. 
Recent FDA approval will drive use of this treatment.15 
The nasal expiratory positive airway pressure (nEPAP) device is another product that 
shows promise as a second-line alternative for patients intolerant of CPAP. This small 
plug is placed in the nose to provide pressure to the upper airway to prevent collapse. It 
works on the premise that at the end of expiration there is no positive pressure in the 
upper airway, no phasic activity of the dilator muscles, and the cross-sectional area of 
the upper airways is significantly narrowed.20 Six clinical trials found a significant 
reduction in AHI and time spent snoring, and decreased oxygen desaturation.20 The 
decreased time spent snoring may benefit patients whose sleeping partners are 
adversely affected by the noise of a standard CPAP machine. It also serves as a good 
alternative for patients who travel frequently, due to its compact size. The product is 
also available without a prescription, making it easily accessible to patients. 
Patient Education 
A Cochrane collaboration report reviewing 30 studies of patient educational, supportive, 
and behavioral interventions showed a positive impact on time spent using their CPAP 
machine in 2047 adults with OSA.20 Patients should be taught basic pathophysiology 
and clinical consequences of OSA. A discussion regarding patient’s expectations and 
risk factors should occur. Patients should be advised to avoid alcohol, opioids, and 
sedative-hypnotic medications, as they diminish respiratory drive, which can be fatal in 
a patient in OSA.1 Weight loss and sleep position should also be discussed since supine 
position can cause an increase of apneic and hypopneic events.1,23 
Sleep Position 
Up to 60% of patients have positional OSA, which is defined as supine AHI greater than 
two times that of non-supine AHI.20,23 The supine position changes upper airway muscles 
to collapse and the diaphragm to elevate. A small randomized, controlled study to 
evaluate the effect of a sleep position modification device in adult participants with 
positional OSA (n = 47) evaluated if sleep hygiene plus the use of a position 
modification device (comprised of tennis balls strapped to the back) compared to the 
control of sleep hygiene education alone could decrease AHI.47 After the intervention, 
both groups found a reduction in supine sleep. Utilization of the sleep position 
modification was significantly more effective than control at preventing supine sleep 
(mean ± SD change from baseline, 99.5 ± 85.2 minutes, P = 0.002). The proportion of 
total sleep time in supine was 8.7% in the study group vs 24% in the control group. 
Weight Loss 
Weight loss alone cannot be considered a curative treatment for OSA.9 If severe sleep 
apnea exists, a trial of weight loss is not the best choice. All patients diagnosed with 
severe OSA should be initiated first on CPAP. Furthermore, all patients diagnosed with 
OSA should be counseled on lifestyle changes.1,11 
In seven randomized, controlled trials comparing the impact of diet, exercise, or both on 
improvement in AHI and on reduction in BMI, physical activity alone did not result in AHI 
reduction. The combination of diet and exercise resulted in a pooled AHI reduction of 
6.04 events/hour with BMI reduction of -2.32 kg/m2.9 None of the studies demonstrated 
a return to normal AHI.9 
Medications 
A Cochrane review of 30 trials of 25 drugs involving 516 participants showed there was 
insufficient evidence to recommend the use of drug therapy of OSA.48 The best support 
in research is for inhaled intranasal corticosteroids for OSA in comorbid chronic rhinitis. 
The intranasal corticosteroid fluticasone can help improve AHI in patients with OSA and 
chronic rhinitis compared to placebo (AHI 23.3 vs 30.3; P < 0.05).48 Larger studies of 
longer duration are needed to determine the effect of intranasal corticosteroids effect of 
AHI change and daytime symptoms. For patients with excessive daytime somnolence 
with OSA, if CPAP is not resolving symptoms, modafinil can be considered adjunctive 
symptomatic therapy.48 Further long-term studies on anti-obesity medications should be 
considered to study the impact of weight-loss on OSA.9 
Follow-up 
Primary care physicians will largely order the testing and arrange initiation of OSA 
treatments. In a non-inferiority, randomized, controlled study, 210 patients with OSA 
were randomized to be followed up at a sleep unit vs a primary care setting in Spain 
over a 6-month period.49 There was no statistical difference in the compliance and blood 
pressure reduction in primary care vs the specialist setting. The primary care setting 
was more cost effective by 60%, but patients had greater levels of improvement in ESS 
scores and patient satisfaction in the specialty sleep unit. 
The American Academy of Dental Sleep Medicine in 2013 recommends follow-up at 6 
months and then annually for all OSAs.50 Follow-up testing is not recommended for OSA 
patients when symptom resolution occurs with CPAP usage.1 Follow-up visits ensure 
patient adherence to PAP devices. Newer PAP machines often have microchips, cards, 
or wireless capabilities to download user information to determine compliance. 
Compliance, often defined at 70% usage or approximately 4 hours per night, is often 
required for third-party coverage of PAP devices. 
Patients who undergo bariatric surgery or those with substantial weight loss (defined by 
AASM as 10% of body weight) should have follow-up PSG testing.1 A number of 
randomized, controlled trials investigating the impact of weight loss on severity of OSA 
have reported that a mean range of weight loss of 10-16% can reduce AHI by 20-50%.9 
Complications of OSA 
Moderate-severe OSA is significantly associated with all-cause mortality.3 The use of 
CPAP reduces mortality rates.15 Further research is needed to make associations 
between many comorbid disease states and OSA.   
Hypertension 
Sleep apnea is thought to induce inflammatory response, oxidative stress, and 
activation of the sympathetic nervous system, which can possibly lead to elevated blood 
pressure.51 In a study evaluating CPAP use over 12 weeks, nocturnal systolic blood 
pressure was lower for each additional hour the CPAP was used nightly.46 In addition, 
the 24-hour mean arterial pressure at 12 weeks post-intervention was lower in CPAP 
than control group (-2.4 mmHg; 95% CI, -5.1 to -05; P = 0.02). 
The Wisconsin Sleep Cohort Study studied 1500 participants over 4 years showing 2.9 
greater incidence of hypertension for participants with AHI > 15 vs < 5 at baseline (OR 
1.5-5.6 with 95% CI).3 However, these results were not replicated in a prospective study 
of 2470 participants over a 5-year period.52 Although an increase in odds ratio for 
incident hypertension and increased AHI occurred, after adjusting for obesity, the 
association between AHI and hypertension was not statistically significant. Thus, the 
causative reason for developing hypertension is multi-variable and cannot be solely 
explained by OSA. 
Diabetes Mellitus 
A small study evaluated the use of CPAP machines for OSA and glycemic control in 
T2DM.53 Patients using a CPAP for > 4 hours per night experienced a reduction of 
postprandial glucose and hemoglobin A1c (n = 25). The reduction of hemoglobin A1c 
significantly correlated with total number of days of CPAP use. The authors concluded 
that correcting OSA with a CPAP could have an important impact for T2DM control. 
The Wisconsin Cohort Study of 1387 participants demonstrated T2DM is more 
prevalent in patients with sleep-disordered breathing but could not make causal 
inferences.54 The Veteran Affairs Connecticut Healthcare System studied a cohort of 
1233 consecutive patients and demonstrated that OSA increases the risk of developing 
T2DM.55 Patients with more severe OSA that used regular PAP devices may reduce 
their risk of developing T2DM. 
Chronic Kidney Disease 
Prevalence of OSA is much greater in patients with CKD.56 CKD may lead to OSA 
through fluid overload narrowing the pharyngeal structures.57 More longitudinal studies 
are needed to determine the association between CKD and OSA.56 There are no 
recommendations for screening CKD patients for OSA. 
Cardiovascular Disease 
In the Wisconsin Sleep Cohort Study, a cross-sectional study of 1500 participants 
determined from 4- to 15-year follow-up data that untreated sleep apnea predicted 
increases in hypertension, depression, cerebrovascular effects, and all-cause 
mortality.3Another longitudinal study in 397 participants in Australia found a higher 
incidence of stroke but no significant association of cardiovascular disease or 
stroke.7 Utilizing non-CPAP treatments does not decrease mortality related to 
cardiovascular disease. No clear survival benefits or reductions in cardiovascular illness 
were associated with MADs.11 
Chronic Obstructive Pulmonary Disease 
Coexistence of chronic obstructive pulmonary disease (COPD) and OSA, also called 
overlap syndrome, occurs in approximately 14% of patients with mild COPD and 11% of 
patients with OSA.58 The Sleep Heart Health Study evaluated 5954 patients and did not 
find a significant difference in the prevalence of OSA among COPD patients and those 
without COPD, suggesting that COPD does not increase your risk of developing 
OSA.59However, in a recent study, 57% of patients with severe COPD requiring referral 
to pulmonary rehabilitation were found to have overlap syndrome.60 It is known that 
overlap patients experience more nocturnal desaturations than patients with either OSA 
or COPD alone. When PSG results were compared between overlap syndrome patients 
and OSA patients, the overlap syndrome group had lower mean arterial blood saturation 
and spent more time in desaturation than the OSA group.61 Patients with overlap 
syndrome when compared to COPD patients alone were also at increased risk of death 
due to cardiovascular disease.14 Nasal CPAP has been associated with decreased 
mortality in patients with overlap syndrome.62 Physicians should give focused patient 
education in avoiding alcohol, sedative-hypnotics, opioids, and any other substance that 
can decrease respiratory drive.58 
Differential Diagnosis 
In contrast to OSA, where airflow is disrupted because of airway obstruction, central 
sleep apnea (CSA) results from temporary failure of the brain to send signals to 
breathe. Because of the lack of respiratory effort occurring, treatment of CSA and OSA 
are very different. CPAP and oral devices may be contraindicated in patients with CSA, 
so accurate diagnosis is important.34 Investigating for other organic causes of 
hypersomnolence and/or insomnia, including hypothyroidism, depression, narcolepsy, 
restless leg syndrome, and circadian rhythm disturbances, should be ruled out. 
Seasonal allergies, chronic rhinitis, primary respiratory diseases, and COPD should also 
be evaluated in patients with loud snoring. 
Further Research 
Multiple areas of OSA need larger randomized controlled trials, including the impact of 
antiobesity medications and weight loss interventions for long-term OSA 
outcomes.9Larger randomized, controlled trials with weight loss > 10% with long-term 
follow-up are necessary to understand the impact of lifestyle interventions for OSA.9 In 
addition, research focusing on the metabolic implications of OSA, including glucose 
regulation and cancer development, is needed. Recent studies showed glucose 
dysregulation and tumor growth may be related to sleep fragmentation.15 Further 
research is also needed in the area of perioperative sleep apnea testing. At this time 
there is no recommendation by the American College of Physicians or AASM for routine 
sleep apnea screening prior to surgery.4 
Conclusion 
The gold standard for diagnosing OSA is PSG, with CPAP as the gold standard 
treatment. Adherence with CPAP is variable. Consider other delivery devices and 
masks types, other PAP devices, surgery, oral appliances, and novel treatments when 
CPAP is not tolerated. Offer all patients education on lifestyle and weight loss. More 
randomized, controlled trials are needed to correlate comorbid conditions such as 
diabetes mellitus, hypertension, and cancer with OSA. Although all-cause mortality is 
higher in patients with OSA, there is yet to be strong clinical evidence demonstrating the 
causative nature of OSA on cardiovascular diseases. 
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